Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

被引:4
|
作者
Shi, Zonggao [1 ,5 ]
Lopez, Jacqueline [2 ]
Kalliney, William [1 ,3 ,5 ]
Sutton, Bobbie [3 ]
Simpson, Joyce [3 ]
Maggert, Kevin [3 ]
Liu, Sheng [4 ,6 ]
Wan, Jun [4 ,6 ]
Stack, M. Sharon [1 ,5 ]
机构
[1] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN USA
[2] Univ Notre Dame, Genom & Bioinformat Core Facil, Notre Dame, IN USA
[3] South Bend Med Fdn, South Bend, IN USA
[4] Indiana Univ Sch Med, Collaborat Core Canc Bioinformat, Indianapolis, IN USA
[5] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN USA
[6] Indiana Univ Sch Med, Dept Med & Mol Genet, United 0States Amer, Indianapolis, IN USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
关键词
CANCER;
D O I
10.1371/journal.pone.0266914
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PurposeThe demand for high-throughput genetic profiling of somatic mutations in cancer tissues is growing. We sought to establish a targeted next generation sequencing (NGS) panel test for clinical oncology practice. MethodsCustomized probes were designed to capture exonic regions of 141 genes selected for the panel, which was aimed for the detection of clinically actionable genetic variations in cancer, including KRAS, NRAS, BRAF, ALK, ROS1, KIT and EGFR. The size of entire targeted regions is 0.8 Mb. Library preparation used NEBNext Ultra II FS kit coupled with target enrichment. Paired-end sequencing was run on Illumina NextSeq 500 at a read length of 150 nt. A bioinformatics workflow focusing on single nucleotide variant and short insertions and deletions (SNV/indel) discovery was established using open source, in-house and commercial software tools. Standard reference DNA samples were used in testing the sensitivity and precision and limit of detection in variant calling. ResultsThe general performance of the panel was observed in pilot runs. Average total reads per sample ranged from 30 million to 48 million, 73% ~82% unique reads. All runs had more than 99% average mapping rate. Mean target coverage ranged from 727x to 879x. Depth of coverage at 50x or more reached 87% of targeted region and 60% of targeted region received 500x or more coverage depth. Using OncoSpan HD827 DNA, which bears 144 variants (SNV/indel) from 80 genes that are within the targeted region on the panel, our somatic variant calling pipeline reached 97% sensitivity and 100% precision respectively, with near 48 million reads. High concordance with orthogonal approaches in variant detection was further verified with 7 cancer cell lines and 45 clinical specimens. ConclusionWe developed a NGS panel with a focus on clinically actionable gene mutations and validated the performance in library construction, sequencing and variant calling. High concordance with reference materials and orthogonal mutation detection was observed.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Clinical Applications and Limitations of Next-Generation Sequencing
    Basho, Reva Kakkar
    Eterovic, Agda Karina
    Meric-Bernstam, Funda
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (03) : 17 - 22
  • [22] A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors
    Luthra, Rajyalakshmi
    Patel, Keyur P.
    Routbort, Mark J.
    Broaddus, Russell R.
    Yau, Jonathan
    Simien, Crystal
    Chen, Wei
    Hatfield, David Z.
    Medeiros, L. Jeffrey
    Singh, Rajesh R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (02) : 255 - 264
  • [23] Challenges adopting next-generation sequencing in community oncology practice
    Ashbury, Fredrick D.
    Thompson, Keith
    Williams, Casey
    Williams, Kirstin
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (05) : 507 - 512
  • [24] Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
    Andres-Zayas, Cristina
    Suarez-Gonzalez, Julia
    Rodriguez-Macias, Gabriela
    Dorado, Nieves
    Osorio, Santiago
    Font, Patricia
    Carbonell, Diego
    Chicano, Maria
    Muniz, Paula
    Bastos, Mariana
    Kwon, Mi
    Luis Diez-Martin, Jose
    Buno, Ismael
    Martinez-Laperche, Carolina
    MOLECULAR ONCOLOGY, 2021, 15 (09) : 2273 - 2284
  • [25] Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
    Zeng, Jia
    Johnson, Amber
    Abu Shufean, Md
    Kahle, Michael
    Yang, Dong
    Woodman, Scott E.
    Vu, Thuy
    Moorthy, Shhyam
    Holla, Vijaykumar
    Meric-Bernstam, Funda
    JCO CLINICAL CANCER INFORMATICS, 2019, 3
  • [26] Next-Generation Sequencing
    Le Gallo, Matthieu
    Lozy, Fred
    Bell, Daphne W.
    MOLECULAR GENETICS OF ENDOMETRIAL CARCINOMA, 2017, 943 : 119 - 148
  • [27] Comparison of Custom Capture for Targeted Next-Generation DNA Sequencing
    Samorodnitsky, Eric
    Datta, Jharna
    Jewell, Benjamin M.
    Hagopian, Raffi
    Miya, Jharna
    Wing, Michele R.
    Damodaran, Senthilkumar
    Lippus, Juliana M.
    Reeser, Julie W.
    Bhatt, Darshna
    Timmers, Cynthia D.
    Roychowdhury, Sameek
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (01) : 64 - 75
  • [28] Diagnostic Utility of Targeted Next-generation Sequencing in Problematic Cases
    Sehn, Jennifer K.
    Hagemann, Ian S.
    Pfeifer, John D.
    Cottrell, Catherine E.
    Lockwood, Christina M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (04) : 534 - 541
  • [29] Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors
    Saotome, Keiko
    Chiyoda, Tatsuyuki
    Aimono, Eriko
    Nakamura, Kohei
    Tanishima, Shigeki
    Nohara, Sachio
    Okada, Chihiro
    Hayashi, Hideyuki
    Kuroda, Yuka
    Nomura, Hiroyuki
    Susumu, Nobuyuki
    Iwata, Takashi
    Yamagami, Wataru
    Kataoka, Fumio
    Nishihara, Hiroshi
    Aoki, Daisuke
    CANCER MEDICINE, 2020, 9 (20): : 7407 - 7417
  • [30] Next-Generation Sequencing and the Clinical Oncology Workflow: Data Challenges, Proposed Solutions, and a Call to Action
    Conway, Jake R.
    Warner, Jeremy L.
    Rubinstein, Wendy S.
    Miller, Robert S.
    JCO PRECISION ONCOLOGY, 2019, 3